Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Bevacizumab Sequential Treatment in Advanced CRC
NCT06856187Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Fudan University. Primary endpoint: Time to treatment failure at 2 years. Started Feb 2025; status: recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06856187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856187.